These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 73293)

  • 1. [Hypnotics and sedatives in liver diseases (summary of session 4)].
    Z Gastroenterol Verh; 1976; (12):203-20. PubMed ID: 73293
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical problems in the application of sedatives in patients with chronic liver disease (author's transl)].
    Becker K
    Z Gastroenterol; 1977 Jun; 15(6):356-61. PubMed ID: 888484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disposition and effects of sedatives and analgesics in liver disease.
    Hoyampa AM; Branch RA; Schenker S
    Annu Rev Med; 1978; 29():205-18. PubMed ID: 348033
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics.
    Schenker S; Hoyumpa AM; Wilkinson GR
    Med Clin North Am; 1975 Jul; 59(4):887-96. PubMed ID: 238085
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolism of phenylbutazone in the liver (author's transl)].
    González Macías J; De Castro del Pozo S
    Med Klin; 1976 Sep; 71(36):1434-8. PubMed ID: 958107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sedatives and liver diseases].
    Franken FH
    Minerva Med; 1973; 64(49):2619-21. PubMed ID: 4727522
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug disposition in liver disease.
    Fruncillo RJ
    Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug disposition and liver disease.
    Wilkinson GR; Schenker S
    Drug Metab Rev; 1975; 4(2):139-75. PubMed ID: 770104
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
    Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in thyroxine-binding capacity in liver diseases].
    Pottkämper G; Gatz J; Schwinn G; Hesch RD; Köbberling J
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():322-5. PubMed ID: 829382
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatic and renal elimation of bromsulphalein in chronic hepatitis, post-inflammatory cirrhosis and obstructive jaundice].
    Babiuch L
    Przegl Epidemiol; 1975; 29(2):159-67. PubMed ID: 1144806
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases].
    Del Prete S; Malacco E; Bonzi G; Natelli A; Roncoroni S; Jalanbo H
    Minerva Med; 1975 Mar; 66(22):1051-7. PubMed ID: 1124151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Benzodiazepines and liver diseases. Pharmacokinetics and pharmacodynamic effects].
    Antoni M; Botta-Fridlund D; Bourlière M; Bun H; Gauthier AP
    Gastroenterol Clin Biol; 1990; 14(5):492-500. PubMed ID: 1973130
    [No Abstract]   [Full Text] [Related]  

  • 15. [Protein-copper complex in primary biliary cirrhosis and other chronic diffuse diseases of the liver].
    Loginov AS; Aruin LI; Shepeleva SD
    Arkh Patol; 1980; 42(4):50-5. PubMed ID: 7396755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Haptoglobin kinetics and enzyme activity in acute hepatitis, mechanical icterus and liver cirrhosis].
    Kallai L; Keler-Bacoka M; Blazkević K; Knĕzević S
    Cesk Gastroenterol Vyz; 1966 Sep; 20(6):398-407. PubMed ID: 5976469
    [No Abstract]   [Full Text] [Related]  

  • 17. [Significance of the liver for the biological activity of drugs].
    Ackermann E
    Dtsch Z Verdau Stoffwechselkr; 1970; 30(1):3-8. PubMed ID: 5501425
    [No Abstract]   [Full Text] [Related]  

  • 18. Sedation in liver disease.
    Br Med J; 1977 May; 1(6071):1241-2. PubMed ID: 861558
    [No Abstract]   [Full Text] [Related]  

  • 19. Major drug interactions: effect of liver disease, alcohol, and malnutrition.
    Hoyumpa AM; Schenker S
    Annu Rev Med; 1982; 33():113-49. PubMed ID: 7044269
    [No Abstract]   [Full Text] [Related]  

  • 20. Anticoagulant interactions.
    Br Med J; 1971 Oct; 4(5780):128-9. PubMed ID: 5113012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.